Filter
363
Filtered Results: 363
Text search:
National
Pharmacovigilance
Policy
Featured
Recommendations
44
New Publications
126
Language
Document type
No document type
204
Guidelines
58
Studies & Reports
46
Strategic & Response Plan
21
Manuals
18
Fact sheets
7
Training Material
5
Situation Updates
3
Infographics
1
Countries / Regions
Kenya
21
Nigeria
15
India
15
Ghana
14
Uganda
14
Western and Central Europe
13
Global
11
Eastern Europe
11
Nepal
10
Rwanda
10
South Africa
10
Namibia
9
Sierra Leone
7
Malawi
7
Ethiopia
7
Tanzania
6
Philippines
5
Congo, Democratic Republic of
5
South–East Asia Region
5
Liberia
5
Cambodia
4
West and Central Africa
4
Bangladesh
4
Russia
4
Zambia
4
Lesotho
3
Benin
3
Senegal
3
Zimbabwe
3
Mozambique
3
Latin America and the Carribbean
3
East and Southern Africa
3
Botswana
3
Ukraine
2
Syria
2
Africa
2
Haiti
2
Asia
2
Middle East and North Africa
2
Eastern Europe and Central Asia
2
Sudan
2
Libya
2
Indonesia
2
Myanmar / Burma
2
Madagascar
2
Eswatini/ Swaziland
2
Pakistan
2
Thailand
1
Gambia
1
Cameroon
1
Laos
1
Burkina Faso
1
Afghanistan
1
Guinea
1
Jordan
1
Western Pacific Region
1
Maldives
1
Lebanon
1
Sri Lanka
1
Yemen
1
Georgia
1
Mali
1
Bhutan
1
Authors & Publishers
Publication Years
Category
Countries
187
Clinical Guidelines
44
Public Health
12
Women & Child Health
6
Capacity Building
5
Key Resources
5
Pharmacy & Technologies
4
Toolboxes
TB
45
Pharmacy
40
AMR
31
COVID-19
23
HIV
17
NTDs
15
NCDs
4
Ebola & Marburg
3
Specific Hazards
2
Refugee
2
Caregiver
2
Planetary Health
2
Rapid Response
1
Cholera
1
Malaria
1
Polio
1
Global Health Education
1
This study addresses part of the Terms of Reference for a scoping report ‘An analysis of approaches to laboratory capacity strengthening for drug resistant infections in low and middle income countries’. It has been produced as a separate report because it is also very relevant for a second stud...
The WHO South-East Asia (SEA) Region bears a high burden of tuberculosis (TB) and MDR-TB. In 2015, the Region accounted for nearly 200 000 or 35% of the global estimated new RR/MDR-TB cases eligible for treatment. Extensively drug-resistant TB (XDRTB) has also been reported from s...
The World Health Organization's fourth Country Cooperation Strategy 2022-2026 is an outcome of a consultative process with inputs from the Ministry of Health, various agencies in the health sector, and other relevant stakeholders. It has been developed to provide strategic direction and support towa...
Waste Management & Research 39(1) DOI: 10.1177/0734242X211029175
Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported ...
Infectious Diseases of Poverty 2014, 3:42
http://www.idpjournal.com/content/3/1/42
Disability inclusive shelter programming enables persons with disabilities to contribute more to their communities, participate more in consultations and decision-making, and facilitate their own protection. The key concepts include: Disability inclusive shelter programming is both a process and an ...
A living WHO guideline on drugs for covid-19
recommended
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...
Global UNIDO Project: Strengthening the local production of essential generic drugs in the least developed and developing countries
Psoriasis, which can involve the skin, nails and joints, is a chronic, painful, disfiguring and disabling noncommunicable disease (NCD) for which there is no cure. It negatively impacts on quality of life. Some of those who suffer from the disease develop chronic, inflammatory arthritis (psoriatic a...
The extensive use of antimicrobials in human and veterinary medicine in recent years has accelerated the emergence and spread of resistant microorganisms. This situation has been worsened by the lack of investment in developing new effective antibiotics. The severity of the consequences is clear to ...
